Telix Pharmaceuticals ASX:TLX 주식 보고서 Telix Pharmaceuticals Limited
ASX:TLX 주식 보고서
TLX 주식 개요 상업화 단계의 바이오 제약 회사인 텔릭스 파마슈티컬스는 호주, 벨기에, 일본, 스위스, 미국에서 암 및 희귀 질환을 위한 치료 및 진단용 방사성 의약품의 개발과 상용화에 주력하고 있습니다. 자세한 내용
Telix Pharmaceuticals Limited 경쟁사 가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Telix Pharmaceuticals 과거 주가 현재 주가 AU$22.98 52주 최고치 AU$23.99 52주 최저치 AU$8.94 베타 2.38 11개월 변경 6.88% 3개월 변경 사항 24.82% 1년 변경 사항 148.97% 33년 변화 249.24% 5년 변화 1,103.14% IPO 이후 변화 2,884.42%
최근 뉴스 및 업데이트
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy
Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma Oct 03
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million. Sep 23 더 많은 업데이트 보기
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy
Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma Oct 03
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million. Sep 23
Consensus EPS estimates fall by 23% Aug 29
Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent Aug 28
Second quarter 2024 earnings: EPS misses analyst expectations Aug 23
Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent Jul 30
Price target increased by 12% to AU$24.04 Jul 24
Price target increased by 10% to AU$20.87 Jul 19 Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024
Price target increased by 14% to AU$21.49 Jul 12
Consensus EPS estimates increase by 10% Jul 12
Price target increased by 11% to AU$18.89 Jun 18 Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million. Jun 15
First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023) Jun 06
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent May 28
Consensus EPS estimates increase by 10% May 22
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 18
Consensus EPS estimates increase by 30% Apr 18 Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024
Now 20% overvalued after recent price rise Apr 12 Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 11
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 09
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent Mar 26
Consensus EPS estimates fall by 19% Mar 14
Price target increased by 7.5% to AU$14.47 Mar 11 Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million. Mar 05
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million. Feb 27
Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022) Feb 23 Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024
Co-Founder exercised options to buy AU$1.7m worth of stock. Jan 23
Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024 Jan 08
Forecast breakeven date pushed back to 2024 Dec 31
Telix Pharmaceuticals Limited Announces Executive Changes Dec 20
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer Dec 19
Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Dec 04
Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS Nov 30
Price target increased by 8.0% to AU$13.37 Nov 22
Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million. Nov 15
Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million. Nov 02
Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591 Oct 19
Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies Oct 18
Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023 Oct 11
New minor risk - Shareholder dilution Sep 06
Forecast to breakeven in 2023 Aug 25
First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.23 loss in 1H 2022) Aug 24
Forecast to breakeven in 2023 Aug 24
Forecast breakeven date moved forward to 2023 Aug 23
Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 15
Forecast to breakeven in 2023 Jul 21
Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023 Jul 13
Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI Jun 24
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million. Jun 22
Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion Jun 19
Price target increased by 7.5% to AU$11.82 Jun 06
Price target increased by 8.8% to AU$10.54 Apr 28
Price target increased by 8.8% to AU$10.54 Apr 19
Insider recently bought AU$343k worth of stock Mar 18
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 28
Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial Feb 20
Consensus EPS estimates fall by 14%, revenue upgraded Jan 25
Forecast breakeven date pushed back to 2024 Jan 18
Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023 Jan 12
Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances Dec 22
Insider recently bought AU$73k worth of stock Dec 16
Telix Pharmaceuticals Limited Announces Leadership Changes Dec 05
Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection Nov 23
Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy Nov 22
Non-Executive Director exercised options to buy AU$3.5m worth of stock. Nov 16
Insufficient new directors Nov 16
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center. Nov 15
Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints Nov 11
Non-Executive Director exercised options to buy AU$3.4m worth of stock. Nov 11
Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Nov 07
Forecast breakeven date moved forward to 2023 Oct 21
Consensus revenue estimates increase by 19% Oct 21
Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM Oct 18 Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022 Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging Oct 14
Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix Sep 30 Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate 주주 수익률 TLX AU Biotechs AU 마켓 7D 0.5% 0.1% -0.02% 1Y 149.0% 13.4% 14.8%
전체 주주 수익률 보기
수익률 대 산업: TLX 지난 1년 동안 16.9 %를 반환한 Australian Biotechs 산업을 초과했습니다.
수익률 대 시장: TLX 지난 1년 동안 17.3 %를 반환한 Australian 시장을 초과했습니다.
가격 변동성 Is TLX's price volatile compared to industry and market? TLX volatility TLX Average Weekly Movement 5.9% Biotechs Industry Average Movement 10.1% Market Average Movement 8.4% 10% most volatile stocks in AU Market 17.2% 10% least volatile stocks in AU Market 3.5%
안정적인 주가: TLX 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: TLX 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 상업화 단계의 바이오 제약 회사인 텔릭스 제약은 호주, 벨기에, 일본, 스위스, 미국에서 암 및 희귀 질환을 위한 치료 및 진단용 방사성 의약품의 개발과 상용화에 주력하고 있습니다. 이 회사는 전립선암 치료용 일루킥스(Illuccix)와 영상 골수염 치료용 TLX66-CDx를 제공합니다. 제품 후보로는 전립선암 치료를 위한 방사성 항체-약물 접합체 TLX591, 신장(신장) 암 치료 및 진단용 TLX250-CDx, 뇌(신경교종) 암 치료용 TLX101-CDx, 골수 조절 치료용 TLX66-CDx, 연조직 육종 치료 및 진단용 TLX300-CDx, 투명세포 신세포 암종 치료용 TLX250 등이 있습니다.
자세히 보기 Telix Pharmaceuticals Limited 기본 사항 요약 Telix Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? TLX 기본 통계 시가총액 AU$7.69b 수익(TTM ) AU$49.19m 수익(TTM ) AU$645.68m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) TLX 손익 계산서(TTM ) 수익 AU$645.68m 수익 비용 AU$240.33m 총 이익 AU$405.35m 기타 비용 AU$356.16m 수익 AU$49.19m
주당 순이익(EPS) 0.15 총 마진 62.78% 순이익 마진 7.62% 부채/자본 비율 2.9%
TLX 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
